研究目的
To assess the functional and anatomic outcomes of intravitreal a?ibercept injection in patients with wet age-related macular degeneration (AMD) refractory to intravitreal bevacizumab or ranibizumab therapy.
研究成果
The present study showed the ef?cacy of a?ibercept treatment in eyes with persistent retinal or SRF under bevacizumab or ranibizumab therapy. A signi?cant anatomical and functional improvement was presented in our study. We also suggested that a?ibercept may have a lesser impact on IOP than the other anti-VEGF agents.
研究不足
The retrospective design of our study is the most crucial limiting factor. A single retina specialist treated all patients using the same OCT-guided pro re nata treatment algorithm and protocol. The absence of a second observer may cause some bias in the measurement of anatomic outcomes in the present study. Additionally, excluding the patients with a follow-up shorter than 6 months under a?ibercept treatment may lead to a bias because patients not content with their treatment might be more prone to terminate the treatment than patients experiencing a successful treatment.
1：Experimental Design and Method Selection:
A retrospective non-comparative study was designed to evaluate the functional and anatomic outcomes of intravitreal a?ibercept injection in patients with subfoveal CNV secondary to AMD refractory to intravitreal bevacizumab or ranibizumab therapy.
2：Sample Selection and Data Sources:
Medical charts of patients treated with intravitreal anti-VEGF (bevacizumab-ranibizumab-a?ibercept) for AMD from January 2014 to January 2017 were reviewed.
3：List of Experimental Equipment and Materials:
Optical coherence tomography (OCT) device (Optovue OCT, V 5.1, RTVue 100-2; Optovue, Fremont, CA, USA), Goldmann applanation tonometer.
4：1, RTVue 100-2; Optovue, Fremont, CA, USA), Goldmann applanation tonometer. Experimental Procedures and Operational Workflow:
4. Experimental Procedures and Operational Workflow: A?ibercept treatment (2 mg/
5：05 cc) were applied every 8 weeks after three monthly loading doses until complete resolution of ?uid. Patients with dry retina after a?ibercept therapy were treated in an as-needed algorithm and were followed up with optic coherence tomography every 4 weeks. Data Analysis Methods:
Statistical Package for the Social Sciences (SPSS) version 20.0 software (IBM, New York, USA) was used for all statistical analyses.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
